Rayca’s AI rapidly designs, screens and optimizes thousands of therapeutic candidates for hard-to-drug targets, leading our owned and partnered therapeutic pipelines from concept to IND-approval. Rayca's platform is a closed-loop process where each data point—from screening, in vitro testing, or preclinical validation—feeds back into the AI models to continuously improve future drug designs.

Our platform integrates potency matrices, dynamic molecular simulations, and high-resolution structural modeling to design highly optimized drug candidates. We specialize in creating a diverse range of therapeutic modalities, including small molecules, cyclic and linear peptides, peptidomimetics, bispecific antibodies, and RNA-based drugs. Leveraging best in class algorithms, we perform large-scale virtual screenings across uncharted chemical and biomolecular spaces to uncover cryptic binding pockets and novel mechanisms of action.